Trial Outcomes & Findings for Evaluate Dental Plaque Benefit of a Preventive Treatment Gel (NCT NCT03546491)

NCT ID: NCT03546491

Last Updated: 2019-09-04

Results Overview

The Turesky Modified Quigley-Hein Index was scored on six surfaces (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual and mesiolingual) to assess plaque on all gradable teeth. Whole mouth average plaque scores were calculated for each subject and tooth surfaces by totaling the scores and dividing by the number of gradable sites examined. the scoring criteria is below; (0) No Plaque; (1) Separate flecks of plaque at the cervical margin; (2) A thin, continuous band of plaque (up to 1 mm) at the cervical margin; (3) A band of plaque wider than 1 mm, but covering less than one third of the side of the crown of the tooth; (4) Plaque covering at least one third, but less than two thirds of the side of the crown of the tooth; (5) Plaque covering two thirds or more of the side of the crown of the tooth.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

32 participants

Primary outcome timeframe

Day 4

Results posted on

2019-09-04

Participant Flow

Participant milestones

Participant milestones
Measure
Overall Study
This was a single center, controlled, examiner-blind, randomized, 2-treatment, 3-period cross-over 4-day partial brushing plaque study. Each participant received Test product 1 (0.4% stannous fluoride preventive gel), and Test product 2 (marketed 0.243% sodium fluoride toothpaste). All subjects saw each test product at least 1 time, for the third period, each subject saw either Test product 1 or Test product 2 for a second time.
Overall Study
STARTED
32
Overall Study
Recieved Test Product 1
32
Overall Study
Received Test Product 2
32
Overall Study
COMPLETED
30
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluate Dental Plaque Benefit of a Preventive Treatment Gel

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall Study
n=32 Participants
This was a controlled, examiner-blind, randomized, 2-treatment, 3-period cross-over 4-day partial brushing plaque study.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
32 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
21 Participants
n=5 Participants
Sex: Female, Male
Male
11 Participants
n=5 Participants
Race/Ethnicity, Customized
Ethnicity · Asian
2 Participants
n=5 Participants
Race/Ethnicity, Customized
Ethnicity · Black or African American
5 Participants
n=5 Participants
Race/Ethnicity, Customized
Ethnicity · Not Reported
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Ethnicity · White Caucasian
24 Participants
n=5 Participants
Region of Enrollment
United States
32 participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 4

The Turesky Modified Quigley-Hein Index was scored on six surfaces (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual and mesiolingual) to assess plaque on all gradable teeth. Whole mouth average plaque scores were calculated for each subject and tooth surfaces by totaling the scores and dividing by the number of gradable sites examined. the scoring criteria is below; (0) No Plaque; (1) Separate flecks of plaque at the cervical margin; (2) A thin, continuous band of plaque (up to 1 mm) at the cervical margin; (3) A band of plaque wider than 1 mm, but covering less than one third of the side of the crown of the tooth; (4) Plaque covering at least one third, but less than two thirds of the side of the crown of the tooth; (5) Plaque covering two thirds or more of the side of the crown of the tooth.

Outcome measures

Outcome measures
Measure
Preventive Gel
n=32 Participants
0.4% stannous fluoride Preventive Gel: 0.4% Stannous Fluoride
Marketed Control
n=32 Participants
0.243 % Sodium Fluoride Marketed Control: 0.243% Sodium Fluoride
Mean Turesky Modified Quigley-Hein Index at Day 4
1.83 score on a scale
Standard Error 0.055
1.96 score on a scale
Standard Error 0.055

SECONDARY outcome

Timeframe: Baseline

The Turesky Modified Quigley-Hein Index was scored on six surfaces (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual and mesiolingual) to assess plaque on all gradable teeth. Whole mouth average plaque scores were calculated for each subject and tooth surfaces by totaling the scores and dividing by the number of gradable sites examined. the scoring criteria is below; (0) No Plaque; (1) Separate flecks of plaque at the cervical margin; (2) A thin, continuous band of plaque (up to 1 mm) at the cervical margin; (3) A band of plaque wider than 1 mm, but covering less than one third of the side of the crown of the tooth; (4) Plaque covering at least one third, but less than two thirds of the side of the crown of the tooth; (5) Plaque covering two thirds or more of the side of the crown of the tooth.

Outcome measures

Outcome measures
Measure
Preventive Gel
n=32 Participants
0.4% stannous fluoride Preventive Gel: 0.4% Stannous Fluoride
Marketed Control
n=32 Participants
0.243 % Sodium Fluoride Marketed Control: 0.243% Sodium Fluoride
Mean Turesky Modified Quigley-Hein Index at Baseline
2.19 score on a scale
Standard Error 0.07
2.22 score on a scale
Standard Error 0.07

SECONDARY outcome

Timeframe: Day 4

Total percent dental plaque area

Outcome measures

Outcome measures
Measure
Preventive Gel
n=32 Participants
0.4% stannous fluoride Preventive Gel: 0.4% Stannous Fluoride
Marketed Control
n=32 Participants
0.243 % Sodium Fluoride Marketed Control: 0.243% Sodium Fluoride
Digital Plaque Imaging
8.14 percentage of plaque area
Standard Error 0.871
10.95 percentage of plaque area
Standard Error 0.871

SECONDARY outcome

Timeframe: Baseline

Total percent dental plaque area

Outcome measures

Outcome measures
Measure
Preventive Gel
n=32 Participants
0.4% stannous fluoride Preventive Gel: 0.4% Stannous Fluoride
Marketed Control
n=32 Participants
0.243 % Sodium Fluoride Marketed Control: 0.243% Sodium Fluoride
Overall Baseline Mean Digital Plaque Imaging
6.57 percentage of plaque area
Standard Error 1.18
7.29 percentage of plaque area
Standard Error 1.18

Adverse Events

Preventive Gel

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

Marketed Control

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Preventive Gel
n=32 participants at risk
0.4% stannous fluoride preventive gel
Marketed Control
n=32 participants at risk
0.243% sodium fluoride toothpaste
Gastrointestinal disorders
Irritation Gum
6.2%
2/32 • Adverse event data were collected for the entire duration of the study for each intervention.
6.2%
2/32 • Adverse event data were collected for the entire duration of the study for each intervention.
Gastrointestinal disorders
Irritation Lip
0.00%
0/32 • Adverse event data were collected for the entire duration of the study for each intervention.
3.1%
1/32 • Adverse event data were collected for the entire duration of the study for each intervention.
Gastrointestinal disorders
Desquamation Oral
3.1%
1/32 • Adverse event data were collected for the entire duration of the study for each intervention.
3.1%
1/32 • Adverse event data were collected for the entire duration of the study for each intervention.
Gastrointestinal disorders
Irritation Mouth
15.6%
5/32 • Adverse event data were collected for the entire duration of the study for each intervention.
6.2%
2/32 • Adverse event data were collected for the entire duration of the study for each intervention.
Infections and infestations
Herpetic Lesion Oral
3.1%
1/32 • Adverse event data were collected for the entire duration of the study for each intervention.
0.00%
0/32 • Adverse event data were collected for the entire duration of the study for each intervention.

Additional Information

Clinical Trial Manager

The Procter & Gamble Company

Phone: 513-622-2489

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place